Matthew Henn

Company: Seres Therapeutics
Job title: Executive VP & CSO
Seminars:
Developing Bacterial Consortia Therapeutics for Infectious and Inflammatory Disease Targets 10:45 am
• Providing an update on Seres’ clinical and pre-clinical pipeline • Discussing candidates including SER-109, which in a Phase 3 Clinical Trial led to a statistically significant reduction in C.difficile recurrenceRead more
day: Day One